Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články
PubMed
28181669
DOI
10.1111/ijd.13543
Knihovny.cz E-zdroje
- MeSH
- acitretin terapeutické užití MeSH
- biologické přípravky terapeutické užití MeSH
- cyklosporin terapeutické užití MeSH
- dermatologické látky terapeutické užití MeSH
- diabetes mellitus epidemiologie MeSH
- dospělí MeSH
- fototerapie MeSH
- hyperlipidemie epidemiologie MeSH
- hypertenze epidemiologie MeSH
- index tělesné hmotnosti MeSH
- keratolytika terapeutické užití MeSH
- komorbidita MeSH
- koronární nemoc epidemiologie MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- methotrexát terapeutické užití MeSH
- obezita epidemiologie MeSH
- opakovaná terapie MeSH
- prevalence MeSH
- psoriáza farmakoterapie epidemiologie terapie MeSH
- registrace MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- stupeň závažnosti nemoci MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- acitretin MeSH
- biologické přípravky MeSH
- cyklosporin MeSH
- dermatologické látky MeSH
- keratolytika MeSH
- methotrexát MeSH
BACKGROUND: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries. METHODS: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST. RESULTS: A total of 1412 psoriatic patients initiating biological treatment were included with a predominance of males (63.4%). The mean patient age was 50.2 years, and approximately 70.5% of patients were either overweight or obese. The mean baseline Psoriasis Area and Severity Index was 19.8, and the Dermatology Life Quality Index was 16.6. More than one-third of patients (41.0%) reported a history of psoriatic arthritis, and a high proportion of patients (49.5%) with cardiovascular risk factors (hypertension [35.2%], hyperlipidemia [27.7%], diabetes mellitus [11.4%], coronary heart disease [4.9%], and obesity [15.2%]) were observed. Most of the patients had been previously treated with phototherapy (85.4%), acitretin (74.0%), methotrexate (65.7%), or cyclosporine (53.1%). CONCLUSION: BIOREP is one of the first registries of patients with psoriasis treated with biologics in Central and Eastern Europe. Our results found a similar or higher prevalence of comorbidities, long disease duration, and high impact on the quality of life among patients included in Western European registries.
